Research progress on interleukin-33 and its roles in the central nervous system

Neuroscience Bulletin

Volumn 27, Issue 5, 2011, Pages 351-357

  Han, Ping ^a   Mi, Wen Li ^a   Wang, Yan Qing ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Central nervous system; Interleukin 33; Signaling; ST2

Indexed keywords

HETERODIMER; INTERLEUKIN 1; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; ISOPROTEIN; MEMBRANE PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; INFLAMMATORY PAIN; NONHUMAN; PAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; TARGET CELL; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; INTERLEUKIN-1; INTERLEUKINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 81355135335     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-011-1025-5     Document Type: Review

References (51)

1. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007, 104(1): 282-287. (Pubitemid 46068023)
2. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008, 3(10): e3331.
3. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106(22): 9021-9026.
4. Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009, 31(1): 84-98.
5. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007, 104(47): 18660-18665. (Pubitemid 350210753)
6. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007, 179(4): 2551-2555.
7. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23(5): 479-490. (Pubitemid 41587888)
8. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998, 187(5): 787-794. (Pubitemid 28115194)
9. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117(6): 1538-1549. (Pubitemid 46871338)
10. Kurowska-Stolarska, Kewin MP, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008, 181(7): 4780-4790.
11. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20(8): 1019-1030.
12. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N, et al. IL- 33 reduces the development of atherosclerosis. J Exp Med 2008, 205(2): 339-346.
13. Verri WA Jr, Guerrero AT, Fukada SY, Valerio DA, Cunha TM, Xu D, et al. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 2008, 105(7): 2723-2728. (Pubitemid 351520580)
14. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004, 173(1): 145-150. (Pubitemid 38797335)
15. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008, 105(31): 10913-10918.
16. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL- 33-a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008, 180(4): 2443-2449.
17. Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJ, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1- driven immunopathology. J Exp Med 2001, 193(7): 785-792. (Pubitemid 32524528)
18. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009, 183(8): 5094-5103.
19. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5): 721-726. (Pubitemid 36222600)
20. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008, 84(3): 631-643.
21. Baekkevold ES, Roussigné M, Yamanaka T, Johansen FE, Jahnsen FL, Amalric F, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163(1): 69-79. (Pubitemid 36759592)
22. Pushparaj PN, Tay HK, H'ng SC, Pitman N, Xu D, McKenzie A, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009, 106(24): 9773-9778.
23. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009, 60(3): 738-749.
24. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al. Production and functions of IL-33 in the central nervous system. Brain Res 2011, 1385: 8-17.
25. Chapuis J, Hot D, Hansmannel F, Kerdraon O, Ferreira S, Hubans C, et al. Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. Mol Psychiatry 2009, 14(11): 1004-1016.
26. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010, 40(2): 200-208.
27. Hayakawa M, Hayakawa H, Matsuyama Y, Tamemoto H, Okazaki H, Tominaga S. Mature interleukin-33 is produced by calpainmediated cleavage in vivo. Biochem Biophys Res Commun 2009, 387(1): 218-222.
28. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009, 183(12): 7890-7897.
29. Towne JE, Garka KE, Renshaw BR, Virca GD, Sims JE. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL- 1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem 2004, 279(14): 13677-13688. (Pubitemid 38468896)
30. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008, 42(3): 358-364.
31. Cullinan EB, Kwee L, Nunes P, Shuster DJ, Ju G, McIntyre KW, et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 1998, 161(10): 5614-5620. (Pubitemid 28519127)
32. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N, et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264(2): 397-406. (Pubitemid 29424443)
33. Bulek K, Swaidani S, Qin J, Lu Y, Gulen MF, Herjan T, et al. The essential role of single Ig IL-1 receptor-related molecule/Toll IL- 1R8 in regulation of Th2 immune response. J Immunol 2009, 182(5): 2601-2609.
34. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S. IL-33 and IL- 33 receptors in host defense and diseases. Allergol Int 2010, 59(2): 143-160.
35. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: an IL-1R/ TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 2009, 30(9): 439-446.
36. Garlanda C, Riva F, Polentarutti N, Buracchi C, Sironi M, De Bortoli M, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci U S A 2004, 101(10): 3522-3526. (Pubitemid 38338228)
37. Funakoshi-Tago M, Tago K, Sato Y, Tominaga S, Kasahara T. JAK2 is an important signal transducer in IL-33-induced NF-kB activation. Cell Signal 2011, 23(2): 363-370.
38. Kuchler AM, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen DR, et al. Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 2008, 173(4): 1229-1242.
39. Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008, 88(11): 1245-1253.
40. Haga Y, Yanagisawa K, Ohto-Ozaki H, Tominaga S, Masuzawa T, Iwahana H. The effect of ST2 gene product on anchorage-independent growth of a glioblastoma cell line, T98G. Eur J Biochem 2003, 270(1): 163-170. (Pubitemid 36056946)
41. Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008, 9(10): 1006-1012.
42. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008, 20(6): 791-800. (Pubitemid 351791523)
43. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009, 183(10): 6469-6477.
44. Andre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem 2005, 95(2): 324-330. (Pubitemid 41457501)
45. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998, 95(12): 6930-6935. (Pubitemid 28278084)
46. Kumar S, Tzimas MN, Griswold DE, Young PR. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997, 235(3): 474-478. (Pubitemid 27326503)
47. Yu JT, Song JH, Wang ND, Wu ZC, Zhang Q, Zhang N, et al. Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease. Neurobiol Aging 2010. [Epub ahead of print]
48. Lee CY, Landreth GE. The role of microglia in amyloid clearance from the AD brain. J Neural Transm 2010, 117(8): 949-960.
49. Kanda M, Ohto-Ozaki H, Kuroiwa K, Tominaga S, Watanabe E, Iwahana H. Elevation of ST2 protein levels in cerebrospinal fluid following subarachnoid hemorrhage. Acta Neurol Scand 2006, 113(5): 327-333.
50. Onda H, Kasuya H, Takakura K, Hori T, Imaizumi T, Takeuchi T, et al. Identification of genes differentially expressed in canine vasospastic cerebral arteries after subarachnoid hemorrhage. J Cereb Blood Flow Metab 1999, 19(11): 1279-1288. (Pubitemid 30176457)
51. Inglis JJ, Notley CA, Essex D, Wilson AW, Feldmann M, Anand P, et al. Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis Rheum 2007, 56(12): 4015-4023. (Pubitemid 350262329)